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Abstract: Two new solvates of the widely used anthelminthic Praziquantel (PZQ) were obtained 
through mechanochemical screening with different liquid additives. Specifically, 2-pyrrolidone and 
acetic acid gave solvates with 1:1 stoichiometry (PZQ-AA and PZQ-2P, respectively). A wide-
ranging characterization of the new solid forms was carried out by means of powder X-ray 
diffraction, differential scanning calorimetry, FT-IR, solid-state NMR and biopharmaceutical 
analyses (solubility and intrinsic dissolution studies). Besides, the crystal structures of the two new 
solvates were solved from their Synchrotron-PXRD pattern: the solvates are isostructural, with 
equivalent triclinic packing. In both structures acetic acid and 2-pyrrolidone showed a strong 
interaction with the PZQ molecule via hydrogen bond. Even though previous studies have shown 
that PZQ is conformationally flexible, the same syn conformation as the PZQ Form A of the C=O 
groups of the piperazinone-cyclohexylcarbonyl segment is involved in these two new solid forms. 
In terms of biopharmaceutical properties, PZQ-AA and PZQ-2P exhibited water solubility and 
intrinsic dissolution rate much greater than those of anhydrous Form A. 




Praziquantel (PZQ, Scheme 1), ((11bRS)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-
hexahydro-4-Hpyrazino [2,1-a]isoquinolin-4-one), is the first-line drug to treat human 
schistosomiasis [1,2], a tropical disease caused by the Schistosoma species worm, which 
affects around 240 million people worldwide and more than 700 million people live in 
endemic areas [3]. For this reason, PZQ is included in World Health Organization (WHO) 
Model List of Essential Medicines for Adults (21st list available at [4]) and for Children 
(7th list available at [5]). The commercial form of PZQ is a racemic anhydrate structure, 
indexed as TELCEU in the Cambridge Structural Database (CSD) [6]. Pure enantiomers 
can be also crystallized separately as hemihydrate forms (CSD codes SIGBUG, SIGBUG01) 
[7,8]. PZQ possesses two additional anhydrate polymorphic forms (Form B and Form C, 
indexed as TELCEU01 and GOYZOM, respectively), obtainable via neat grinding PZQ 
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Form A [9,10]. Despite the absence of hydrogen bond donor groups in the molecular 
structure (Scheme 1), PZQ shows an interesting propensity to form a variety of 
multicomponent systems. A series of PZQ cocrystals with different dicarboxylic acids (i.e., 
oxalic, malonic, succinic, maleic, fumaric, glutaric, adipic and pimelic) were attained by 
means of liquid-assisted grinding (LAG) with acetone or acetonitrile. Recently, our group 
reported a hemihydrate form of racemic PZQ (indexed as WUHQAU), obtained via LAG 
in a two-step mechanochemical treatment when the commercial PZQ (Form A) is used, or 
in a one-step in the case of PZQ Form B [11]. Both in the case of PZQ cocrystals with 
dicarboxylic acids and in the racemic hemihydrate, the PZQ adopts an anti-conformation 
of the C=O groups of the piperazinone-cyclohexylcarbonyl segment, whereas 
commercially available PZQ Form A has the syn stereochemistry [6,11] (Figure 1). 
 
Scheme 1. Chemical structure of Praziquantel (a), acetic acid (b) and 2-pyrrolidone (c). 
 
Figure 1. Molecule of PZQ in (a) syn and (b) anti conformations. 
New solvates are discovered either by chance during a specific manufacturing 
process or through systematic polymorph screening programs. Most screening methods 
are based on solution crystallization techniques (i.e., in the presence of excess solvent) 
where only the most stable solvate is likely to be obtained [12]. In this study, we explore 
the use of mechanochemistry, which emerged as particularly prominent method [13] for 
the discovery of multicomponent molecular solids [14]. In this context, one can find 
grinding in the presence of a minor quantity of a certain solvent [15]. This technique, as 
might be expected, seems to provide greater molecular mobility than neat grinding, thus 
it is promising for the discovery of alternative crystalline forms. This method has also been 
documented as effective for inducing specific polymorph transformations and for 
discovering different solid forms (including new crystal forms—e.g., cocrystals—that 
cannot be obtained easily by alternative approaches) [16]. Even though a few systematic 
studies about the mechanochemical synthesis of solvates are reported [17–20], the solvate 
outcome is often regarded as an undesired by-product rather than its main goal [16,21]. 
Here we present a mechanochemical screening study for the search of possible 
solvated forms of PZQ, which, as previously said, has displayed an interesting solid-state 
behavior, forming a variety of anhydrous and hydrate forms by mechanochemistry, and 
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is thus an excellent candidate for the formation of novel multicomponent crystalline 
phases. The knowledge on its crystalline features and the discovery of new crystalline 
phases might also help overcoming some of the limitations related to this important and 
essential drug for the health of humans and animals. Further, in the case of PZQ, the 
knowledge about the existence of solvated forms is paramount, due to the fact that, in 
pharmaceutical industry, solution crystallization is a critical step for the manufacturing 
and production of PZQ, and PZQ tablets are commonly manufactured also using wet 
granulation process, including in some cases the use of organic solvent-based wet 
granulation [22]. 
We survey the solid form landscape of PZQ by mechanochemistry in the presence of 
eight commonly used solvents namely nitromethane, acetonitrile, 1,4-dioxane, ethyl 
acetate, ethanol, 2-pyrrolidone, acetic acid and methanol. Of these, only acetic acid and 2-
pyrrolidone (whose structures are also reported in Scheme 1) gave two new solid forms, 
both monosolvates (PZQ-AA and PZQ-2P). The two solvates were fully characterized, 
revealing some interesting solid-state features and in vitro dissolution profiles. 
2. Materials and Methods 
2.1. Materials 
Praziquantel (PZQ, (11bRS)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4-H-
pyrazino[2,1-a]isoquinolin-4-one)) was of Ph. Eur. grade and kindly donated by Fatro 
S.p.a. (Bologna, Italy). Nitromethane, acetonitrile, 1,4-dioxane, ethyl acetate, ethanol, 
methanol, 2-pyrrolidone and acetic acid of reagent grade were from SIGMA-Aldrich 
(Milano, Italy). The HiPersolv Chromanorm methanol used for the HPLC analysis was 
purchased from VWR Chemicals (BHD PROLABO, Milano, Italy). 
2.2. Preparation of Praziquantel Solvates 
The grinding experiments were performed using a Retsch vibrational mill MM200 
(Retsch, Germany) and stainless steel jars of 25 mL with two stainless steel balls with a 
diameter of 7 mm. PZQ Form A, commercially available, was accurately weighted (200 
mg) and shaken for 30 min at 25 Hz in the presence of a suitable liquid (ranging between 
10 and 100 µL, corresponding to a η from 0.05 to 0.5 µL mg−1) [23]. Snap closed grinding 
jars were used to minimize liquid evaporation. After a set of preliminary trials with 
several solvents (nitromethane, acetonitrile, 1,4-dioxane, ethyl acetate, methanol, ethanol, 
2-pyrrolidone and acetic acid) 2-pyrrolidone and acetic acid were used for the preparation 
of PZQ-2P and PZQ-AA, respectively, starting from the commercial form of PZQ (Form 
A). Each experiment was carried out at least twice to ensure reproducibility. In a typical 
30 min LAG experiment at 25 Hz, from a starting temperature ranging about 25 °C, the 
increase in the temperature of the reaction mixture during grinding was typically around 
5 °C. Powder temperature inside the jar was measured as previously reported [24]. 
The same PZQ-2P and PZQ-AA could be also obtained through a LAG process in the 
presence of 2-pyrrolidone and acetic acid starting with PZQ Form B. Anhydrous Form B 
was previously synthetized by neat grinding as reported in foregoing studies [9]. Besides, 
unsuccessful LAG experiments were conducted in the presence of ethanol and ethyl 
acetate from Form B. Similarly to the case of PZQ hemihydrate [11], the quantity of liquid 
added was not significant, since the same patterns were collected in all the experiments. 
Therefore, to simplify the preparation of the sample and the relative comparison, an 
equimolar ratio between the components was selected as the main production method in 
the case of Form B. 
For comparison purposes, slurry experiments were also performed on Form A in the 
presence of acetic acid and 2-pyrrolidone. Each experiment was carried out at least twice. 
A large excess of solid was added to 3 mL of each solvent and left under stirring at room 
temperature in screw-cap vials for 7 days and the solid samples were checked by powder 
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X-ray diffraction. Specifically, the PZQ concentration of the suspensions was 0.77 g/mL 
and 0.17 g/mL in the acetic acid and 2-pyrrolidone, respectively. 
2.3. Characterization of Praziquantel Solvates 
2.3.1. Thermal Analyses 
Differential Scanning Calorimetry (DSC) was conducted using a Mettler Toledo 
DSC822e system; about 2 mg of the samples were accurately weighted, put in a 40 µL 
aluminum perforated crucible and analyzed by heating from 30 to 160 °C at 10 °C/min 
under nitrogen atmosphere. For the hot stage microscopy (HSM) analysis, some grains of 
powder were positioned in a microscope slide and then observed upon heating from RT 
to about 150 °C in a hot stage system Mettler Toledo FP5. PZQ Form A, PZQ-AA and PZQ-
2P were observed using a Reichert Biovar microscope with micro ocular MD-300 and us-
ing the software Webcam Companion for data collection. 
2.3.2. FT-IR Spectroscopy 
The samples were analyzed using a Perkin-Elmer System 2000 FT-IR instrument on 
compressed disc prepared by gently grinding the sample in an agate mortar with anhy-
drous KBr (in a sample to KBr wt ratio of 1:15) and tableting with a hydraulic press (Perki-
nElmer, Norwalk, CA, USA). The range observed was from 400 to 4000 cm−1, the resolu-
tion used was 4 cm−1 with a step of 1 cm−1 and scan number of 3. 
2.3.3. Powder X-ray Diffraction (PXRD) 
Powder X-Ray Diffraction analyses were conducted by means of a Panalytical X’Pert 
Pro Diffractometer, with a RTMS X’celerator detector (Panalytical, Almelo, Netherlands) 
and a Ni-filtered Cu Kα radiation (λ = 1.5418 Å). About 20 mg of the sample was gently 
pressed on a sample holder with a glass slide to give a flat surface and subsequently ana-
lyzed. The data were collected in the 2θ range of 3–40° using a step size of 0.0334° and a 
scan speed of 0.142° s−1. 
2.3.4. Synchrotron X-ray Powder Diffraction and Solvate Structure Solution 
The diffraction patterns of PZQ-AA and PZQ-2P were collected at the X-ray diffrac-
tion beamline (XRD1) of Elettra Synchrotron, Trieste, Italy [25,26] in transmission mode, 
at room temperature (25 °C) with a monochromatic wavelength of 0.700 Å (17.71 KeV) 
using a Pilatus 2M hybrid-pixel area detector (Dectris, Baden-Daettwil, Switzerland) at a 
working distance of 400 mm, using a 100 µm aperture. Both the solvated forms have been 
packed in borosilicate capillaries with a 500 µm diameter (10 µm wall thickness). The two-
dimensional powder patterns have been integrated using Fit2D program (2018, ESRF, 
Grenoble, France) [26,27], after preliminary calibration of hardware setup, using a capil-
lary (Hilgenberg GmbH, Malsfeld, Germany) filled with LaB6 standard reference powder 
(NIST 660a, National institute of Standard and Thecnology, U.S. Department of Com-
merce). 
 The structure of the two solvated forms were solved by direct space methods, 
through a simulated annealing (SA) protocol using EXPO2014 [28]. The starting structural 
model containing one TELCAQ molecule [29] and one molecule of acetic acid and one of 
2-pyrrolidone was built with Material studio software v 7.0. (MS) (Biovia, San Diego, USA) 
[30] and then geometrically optimized by the Dmol3 code implemented in MS. During the 
SA the cyclohexyl group of the PZQ molecule was allowed to freely rotate. 
2.3.5. Scanning Electron Microscopy (SEM) 
A JEOL JSM-5510LV Scanning Electron Microscope (Jeol Ltd, Welwyn, UK) was used 
for imaging on gold metallized samples. 
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2.3.6. Solid-State NMR Measurements 
Solid-state NMR (SSNMR) measurements were collected on a Bruker Advance II 400 
instrument (Bruker GmbH, Manheim, Germania) operating at 400.23 and 100.65 MHz for 
1H and 13C nuclei, respectively. Cylindrical zirconia rotors (4 mm o.d.) were used with a 
sample volume of 80 µL and spun at 12 kHz. In all the analyses a RAMP-CP pulse se-
quence (1H 90° pulse = 3.05 µs), TPPM 1H decoupling with a radio frequency field of 75 
kHz were used. In total, 124 transients were acquired with 3 ms of contact time and a 
relaxation delays of 20 s. The chemical shift scale was referenced through the resonance 
of glycine (13C methylene signal at 43.5 ppm) which was used as an external standard. 
2.3.7. Periodic DFT Geometry Optimization 
Periodic density-functional theory (DFT) calculations were used to verify the accu-
racy of the crystal structure determinations from powder X-ray data, as well as to simulate 
the solid-state NMR spectra. The calculations were performed using a plane-wave DFT 
code CASTEP19 [31]. The experimental crystal structures of PZQ-AA and PZQ-2P were 
converted into CASTEP input format using the program cif2cell [32]. 
Geometry optimization of the crystal structures was carried out with PBE [33] func-
tional combined with many-body dispersion (MBD*) [34–36] semiempirical correction 
scheme. The plane wave basis set was truncated at 650 eV cutoff and ultrasoft on-the-fly 
generated pseudopotentials were used. The 1st electronic Brillouin zone was sampled 
with a 2π×0.05 Å−1 k-point spacing. The geometry optimization was performed in a 2-step 
process: first the atom coordinates were optimized while keeping the unit cell parameters 
fixed at their experimental values; in the subsequent optimization step the unit cell pa-
rameters were optimized together with the atom coordinates. Throughout both optimiza-
tion steps the crystal structures were subjected to the space group symmetry constraints. 
Geometry optimization was conducted under the following convergence criteria: maxi-
mum total energy change 2 × 10−5 eV/atom; maximum atom displacement 10−3 Å; maxi-
mum atomic force 0.05 eV Å−1; residual stress 0.05 GPa. The residual stress criterion was 
only used in the case of variable cell geometry optimization. 
The geometry-optimized structures were compared with their experimental counter-
parts, and the root mean square Cartesian displacement (RMSCD) was found to be 0.294 
for PZQ-AA and 0.24 for PZQ-2P, both within the 0.35 Å limit signifying reliable structure 
determination [37]. 
2.3.8. GIPAW-DFT 
The optimized crystal structures were used for modelling SSNMR spectra. NMR pa-
rameters were calculated using the CASTEP implementation of GIPAW method [38]. The 
plane wave cutoff was set to 1000 eV, the standard and fine FFT grid scales were set to 2 
and 3, respectively. All other calculation parameters remained the same as for the geom-
etry optimization. The calculated chemical shieldings were converted into chemical shift 
using a reference shielding of 170 ppm. The spectral lines were drawn with Lorentzian 
curves with 1 ppm HWHM. 
2.3.9. Water Solubility and Intrinsic Dissolution Rate 
The solubility of the samples was analyzed by preparing 10 mL of saturated solutions 
of each sample in distilled water, kept under agitation in the dark for 48 h. Then, the so-
lutions were filtered using a membrane (pore size 0.45 µm) and diluted 1:200 with the 
mobile phase prior to injection, using the previously reported HPLC method [9]. Each 
analysis was conducted in triplicate and the average was reported. 
For the intrinsic dissolution rate determinations, about 150 mg of the samples were 
inserted in the sample holder and pressed using a hydraulic press (PerkinElmer, Norwalk, 
CA, USA) for 1 min at 1 ton. The sample surface area obtained was of 0.785 cm2 and the 
entire sample holder with the compressed powder was dipped in a vessel containing 1 L 
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of distilled water kept at 37 °C. The system used was a Hanson Research SR8 Plus disso-
lution test station and the paddles were positioned at 3.5 cm from the tablet surface, with 
a rotation speed of 100 rpm. About 2 mL of the dissolution medium were withdrawn 
every ten minutes till 60 min and immediately replaced with an equal amount of thermo-
stated distilled water. After a 1:20 dilution with the mobile phase, the aliquots were ana-
lyzed using the same HPLC method as the solubility measurements. Triplicated analyses 
were performed and the mean (±S.D.) was calculated at each time point. The amount of 
the dissolved drug per unit area over time was indicated by the slope of the curves, ob-
tained through a linear regression method. The dissolution behavior of the samples was 
compared and the curves were considered statistically different when p values did not 
exceed 0.05. 
2.3.10. Physical Stability 
PZQ-AA and PZQ-2P (2 batches each) were kept in a desiccator at room temperature 
in the dark. Every month over a period of 18 months, solid samples were retrieved and 
analyzed via PXRD measurements. 
Further, PZQ-AA and PZQ-2P physical stability upon thermal and mechanical treat-
ment was tested. In particular, the monosolvated samples were heated at constant tem-
perature of 50 °C under vacuum over-night and the obtained product assayed by PXRD. 
PZQ-AA and PZQ-2P were also ground for 200 min at 25 Hz and again their solid state 
was assessed by means of PXRD. 
3. Results 
A crystal form screening of PZQ was conducted by milling pure anhydrous PZQ 
Form A in the presence of eight commonly used solvents. The solvents, their main physi-
cochemical parameters and the outcomes are reported in Table 1. It can be seen, besides 
the pure anhydrous PZQ Form A, that two new crystalline forms are obtained from acetic 
acid and 2-pyrrolidone. PXRD measurements, SEM analyses and thermal methods were 
applied to characterize the obtained crystal forms. It was found that all the new crystal 
forms should be assigned to PZQ solvates, which were labeled as PZQ-AA and PZQ-2P, 
respectively. These liquid additives enabled the formation of the same solvates when PZQ 
Form B was used as starting material (as also reported in Table 1). Moreover, the for-
mation of the new phases was complete, since neither with PZQ A nor with PZQ B evi-
dence of the starting materials was found. Slurry experiments of PZQ Form A suspended 
in acetic acid and 2-pyrrolidone gave origin to the same solvates. 
Table 1. Physicochemical parameters of the solvents and observed Praziquantel solid forms via grinding in the presence 
of each liquid additive. 
Solvent 
Boiling  
Point ( °C) 
[39] 
H donor 














acetic acid 118 112 45 64 370.80 
A AA 
B AA 
acetonitrile 81.6 19 40 75 522.95 A A 
1,4-dioxane 101.3 0 37 55 372.17 A A 
ethanol 78.3 86 75 54 618.87 
A A 
B A 
ethyl acetate 77.1 0 45 55 300.64 
A A 
B A 
methanol 64.7 98 66 60 808.26 A A 
nitromethane 101.0 22 06 85 587.22 A A 
2-pyrrolidone 245.0 36 77 85 789,61 [42] 
A 2P 
B 2P 
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As visible in Table 1 and Figure 2, the recurrent pattern of the solid recovered from 
the LAG experiments was Form A (these PXRD patterns are reported in Figure S1, with 
indication of the solvent used). Even changing the parameter η [23] (from 0.05 to 0.5 µL 
mg L−1), the collected form is structurally identical to the starting form. 
Likewise, when starting from anhydrous Form B, the conversion from Form B to 
Form A was promoted. In this case milling with liquid additive (ethyl acetate and etha-
nol), led to polymorph interconversion, as already known for other substances [14] even 
if not documented yet for PZQ. 
 
Figure 2. Sketched diagram of solid forms conversion by milling in the presence of different liquid additives. 
PXRD patterns of the two obtained PZQ solvates obtained by grinding are shown in 
Figure 3, whilst the diffractograms of the solvates obtained by slurry procedure are re-
ported in Figures S2 and S3. The diffraction peak positions of PZQ-AA and PZQ-2P are 
clearly different both from the known (starting) PZQ Form A, and from other known PZQ 
solid forms. However, the PXRD patterns of PZQ-AA and PZQ-2P are quite similar, which 
suggests that these two solvated forms should be isostructural [43]. The main reflections 
of PZQ-AA were at 6.21, 9.17, 14.90, 15.49, 17.69, 19.20, 20.85, 21.20, 22.57, 23.08 and 28.57° 
of 2θ. For PZQ-2P the main peaks were the following: 6.19, 9.11, 10.09, 14.85, 17.47, 17.83, 
19.23, 20.30, 22.23, 22.87, 23.23 and 28.48° of 2θ (Figure 3). 
The two new solid forms exhibited some interesting differences in the habitus mor-
phology (Figure 4). In the case of PZQ-AA SEM images showed layered blocks with al-
most flat particles, with a rough surface presenting some holes. Differently, in PZQ-2P the 
flat surface of the agglomerates is almost entirely covered by very thin needles somehow 
recalling the habitus of commercially available Form A, but much smaller in size. 
The DSC curves of PZQ solvates are shown in Figure 5. It is noteworthy that each 
new phase was characterized by one single endothermic event in the considered temper-
ature range, corresponding to the melting point at 72.26 °C (−74.15 J/g) for PZQ-AA and 
at 85.69 °C (−74.48 J/g) for PZQ-2P. At the Hot Stage Microscopy an analogous thermal 
behavior was noticed in both PZQ-AA and PZQ-2P cases (reported in Figure S4): at the 
temperature where the endotherm was seen at the DSC curve, the solid collapses forming 
a complete liquid phase. Recrystallization upon heating was evident starting from 88 °C 
with the appearance of thin needles, much smaller than original PZQ Form A crystal. The 
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acicular crystals then melted in a temperature range compatible with the previously re-
ported anhydrous Form B [9], and after that event no further crystallizations upon heating 
were noticed. 
 
Figure 3. PXRD patterns of PZQ-AA (blue), PZQ-2P (red) and anhydrous Form A, commercially 
available (black) (wavelength: 1.5418 Å—in-house lab diffractometer). 
 
Figure 4. SEM images of samples obtained by mechanochemical synthesis: PZQ-AA (75×, left, 370×, middle and 1500×, 
right), PZQ-2P (70×, left, 370×, middle and 1800×, right) compared to raw PZQ Form A (75×, left, 270×, middle, and 1400×, 
right). 




Figure 5. DSC of PZQ-AA (blue) and PZQ-2P (red). 
After these preliminary characterizations, to improve the signal-to-noise ratio at high 
2θ angle the crystal structure of both solvated PZQ varieties was solved from the synchro-
tron X-ray powder diffraction data, presented in Figure 6. The higher crystallinity of these 
samples with respect to anhydrous forms previously prepared by neat grinding [9,10] 
along with the typical high signal to noise ratio allowed an undoubted indexing using the 
program EXPO2014 [28]. Both the samples belong to a P-1 triclinic unit cell with volume 
of 997.16 and 1058.04 Å3 for the PZQ-AA and PZQ-2P, respectively, very similar to the vol-
ume of the bis(Praziquantel) adipic acid called TELCAQ (CCDC 896766) [6,29]. 







Temperature ( °C) 




Figure 6. Rietveld refinement profile fit (obtained after the simulated annealing with EXPO14) of PZQ-AA (up) and PZQ-
2P (bottom): in blue the experimental pattern (recorded using Synchrotron radiation, wavelength: 0.700 Å), in red the 
calculated one. The residuals are displayed on the bottom in gray and the reflection ticks in blue. 
The number of formula units per unit cell is Z = 2 and Z’ = 1, containing 4 molecules 
in the unit cell and 1 independent molecule of PZQ and 1 independent molecule of solvent 
in the asymmetric units, in agreement with SSNMR results (see below), with a reasonable 
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density value of 1.240 g·cm−3. A first whole powder pattern fitting (Pawley method) on the 
experimental powder pattern resulted in a good Rwp of 5.36% and 4.07% for PZQ-AA 
and PZQ-2P, respectively. The refined unit cell parameters obtained for PZQ-AA and 
PZQ-2P are reported in Table 2. The solutions showing the best agreement with experi-
mental data are shown in Figure 6. The final Rietveld refinement, where soft restrains on 
the atom distances (±0.03 Å) and angles (±0.1°) were applied, was performed in TOPAS 
V5 resulted in an R-Bragg factor of 3.32% and 2.58% for the PZQ-AA and PZQ-2P solvates, 
respectively. Notwithstanding the novel solvates show a triclinic unit cell with volume, 
cell parameters and crystal packed similar to the hemihydrate structure already published 
[11] the crystal packing comparison (see Figure S5) shows the main difference is due to 
the slippage of PZQ layers caused by the bulkiness of acetic acid and 2-pyrrolidone com-
pared to water and to the hydrogen bond linkage between layers in the hemihydrate. 
Table 2. Crystallographic data for PZQ solvates (refined unit cell parameters at ambient tempera-
ture). 
Phase PZQ-AA PZQ-2P 
Empirical Formula C19H24N2O2·(C2H4O2) C19H24N2O2·(C4H7NO) 
Formula weight 372.46 397.51 
Crystal system triclinic Triclinic 
Space group P-1 P-1 
a (Å) 6.0762 (2) 6.1839 (2) 
b (Å) 11.6197 (4) 12.2615 (3) 
c (Å) 14.5619(8)  14.5539 (5)  
Volume (Å3) 997.16 1058.04 
α (°) 97.292(3) 93.823(2) 
β (°) 98.851 (3) 100.064 (2) 
γ (°) 96.987 (2)  101.693(1) 
Density (g·cm−3)  1.240 1.248 
Z 2 2 
R-Bragg factor (%) 3.32 2.58 
wR factor (%)  4.70 4.04 
Goodness of fit 4.65 3.79 
In both structures (Figure 7) the acetic acid and 2-pyrrolidone showed a strong inter-
action with the PZQ molecule via hydrogen bond, O1-O4 of 2.524 Å and O1-N3 of 2.760 
Å for the PZQ-AA and PZQ-2P, respectively, as also attested by FT-IR analysis in both 
cases (see following Figure S6). 




Figure 7. Capped-stick representation of the proposed structure of PZQ-AA (left) and PZQ-2P (right) viewed along a axis. 
The FT-IR of PZQ-AA and PZQ-2P are reported in Figure S6: the presence of inter-
molecular hydrogen bonds between PZQ and the solvent molecules was displayed by the 
shift of various bands. In particular, a displacement toward lower wavenumbers of the 
carbonyl stretching vibrations of heterocyclic carbonyl (originally at 1651 cm−1 and ob-
served at 1638 cm−1 in both PZQ-AA and PZQ-2P) may result from the decreased electron 
density of the carbonyl group when H-bonds are formed. Conversely, the changes in the 
carbonyl region cannot be inferred to conformational variation, due to the fact that both 
carbonyl groups are oriented in a syn conformation in both Form A and new solvates. 
Looking at the carbonyl stretching vibration of the solvents, in both solvates spectra, the 
pronounced ν(C=O) signals of the solvents are still noticeable and again downward 
shifted. A further diagnostic range in the spectrum is the 3500–3200 cm−1 interval [ν(N-
H)], where a downward shift of the above-mentioned signal is visible in the solvate (orig-
inally present in the 2-pyrrolidone at 3488–3474 cm−1 and observed at 3243 cm−1 in PZQ-
2P). This signal, absent in PZQ Form A, confirms the presence of 2-pyrrolidone in the 
structure. As for PZQ-AA, in the 3550–2500 cm−1 region, the broad bands of the OH- and 
CH-vibrations is very complex: only two signals ranging about 2600 cm−1 are undoubtedly 
attributable to acetic acid in the solvate spectrum. 
The SSNMR analysis was instrumental in assisting the structure solution from pow-
der data, checking the reliability of the solved structure in combination with DFT calcula-
tions [44,45] and evaluating possible hydrogen bond interaction between PZQ and the 
solvent molecules. Indeed, it is well known that in the case of molecular crystals, SSNMR 
can provide several information such as number of independent molecules per unit 
cell,[46] presence of solvent molecules in the crystal and assessment of the stoichiometry 
[47], identification of different crystal forms [46,47], evaluation of hydrogen bond interac-
tions and network [48,49]. 
In the case of the samples under investigation, the SSNMR analyses highlighted the 
marked differences between the two solvates, in addition to those with original PZQ Form 
A and B. The average full width at half maximum (FWHM) value for the signals indicates 
a low degree of crystallinity of the samples (FWHM ~ 140 and 150 Hz for PZQ-AA and 
PZQ-2P, respectively) in agreement with the typical limited crystallinity of a sample ob-
tained by grinding in comparison to those obtained by solution crystallization. Figure S7 
reports the 13C CPMAS SSNMR spectra of PZQ-AA and PZQ-2P, with the assignments of 
the relevant resonances, together with those of PZQ Form A and B used as a comparison. 
Table 3 reports experimental and computed 13C chemical shifts with assignments for both 
PZQ-AA and PZQ-2P. The presence of the solvent molecules can be easily detected by the 
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peaks at 172.1 (COOH) and 19.7 (CH3) ppm for PZQ-AA and at 177.5 (C=O) and 19.4, 28.9 
and 40.4 (CH2) ppm for PZQ-2P. In the case of PZQ-AA, one of the C=O signal is not visi-
ble, due to the overlapping with the COOH signal of acetic acid (172.1 ppm), while in the 
case of PZQ-2P the additional C=O is easily recognized. In both spectra, the number of 
signals is consistent with the presence of one PZQ and one solvent molecule in the asym-
metric unit. Despite the intrinsic quantitative limitations of the CPMAS experiment, an 
accurate integration of the signals confirms the 1:1 stoichiometry for both solvates. Indeed, 
since we are comparing the same group (C=O) with similar limited mobility, we can safely 
suppose nearly equal cross-polarization rates (i.e., TIS) and 1H T1ρ values. Similar, the ap-
proach was successfully tested for other systems [50]. The position of the C=O C4 signal, 
at higher frequencies in PZQ-AA (166.8 ppm) and PZQ-2P (165.7 ppm) with respect to 
that of PZQ Form B (164.3) may be taken as evidence of their involvement in intermolec-
ular hydrogen bonding with the solvent molecules [51]. 
The calculated NMR parameters show excellent agreement with the experimental 
ones (Figure S8, S9 and Table 3). The disagreement between the calculated and experi-
mental 13C NMR signal for the carboxylic carbon of PZQ-AA may be attributed to the 
general difficulty encountered when modelling electron distribution around the func-
tional groups with ionizable protons [52] using semi-local DFT functionals such as PBE. 
In addition, comparison of the calculated and experimental NMR shifts by means of RMS 
error once again revealed excellent agreement (RMSE = 2.09 and 1.83 ppm). These data 
definitely confirm the reliability of the structure solved from PXRD data. 




δiso(exp)/ppm δiso(calc)/ppm * δiso(exp)/ppm δiso(calc)/ppm * 
7’ C=O 172.1 172.68 172.9 173.22 
4 C=O 166.8 167.92 165.7 166.66 
11a Cq 133.1 135.96 133.4 135.75 
7a Cq 134.8 138.03 133.4 137.14 
8 CH(ar.) 129.1 132.30 128.1 131.17 
11 CH(ar.) 124.7 126.84 124.6 126.89 
10 CH(ar.) 126.7 128.66 128.1 130.88 
9 CH(ar.) 126.7 128.91 127.4 130.10 
11b CH(aliph.) 53.7 53.42 54.0 54.2 
3 CH2 46.4 45.51 47.2 46.3 
1 CH2 43.3 41.07 44.3 42.80 
1’ CH(aliph.) 39.8 39.06 39.7 39.63 
6 CH2 37.2 34.71 37.6 34.84 
6’ CH2 28.9 27.68 28.9 27.22 
2’ CH2 28.9 27.38 28.9 28.41 
7 CH2 26.4 25.30 27.8 26.22 
4’ CH2 27.0 25.61 25.8 25.05 
3’ CH2 26.4 25.46 25.8 24.37 
5’ CH2 25.0 23.60 25.8 24.58 
AA ** COOH 172.1 177.13   
AA CH3 19.7 18.03   
2P CH2   19.4 19.09 
2P CH2   28.9 28.16 
2P  CH2   40.4 41.48 
2P CONH   177.5 178.94 
* The calculated chemical shieldings are reported in Table S1. ** AA and 2P mean acetic acid and 
2-pyrrolidone, respectively. 
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The water solubility (after 48 h at 25 °C) and the intrinsic dissolution rate were also 
carried out for the new solid forms and compared to anhydrous PZQ Form A. PZQ-AA 
reached a concentration of 311.91 ± 15.22 mg/L after 48 h while for PZQ-2P was 340.27 ± 
23.18 mg/L, both far superior to that reported at the same temperature for Form A [10]. 
This is in agreement with commonly described behavior of the solvated form to be more 
soluble than the corresponding anhydrous form [12]. Proportionally to the solubility, the 
intrinsic dissolution rate in water at 37 °C was enhanced in the new forms as reported in 
Figure 8: values of 0.0563 ±0.0013 and 0.0640 ± 0.0072 mg/cm2/min were recorded for PZQ-
AA and PZQ-2P, respectively, about double than that of PZQ Form A (0.0312 ± 0.00283 
mg/cm2/min). The statistical comparison between the PZQ-AA and PZQ-2P value did not 
reveal any significant difference, which was conversely detected when comparing the IDR 
of both solvates with the one of Form A. 
 
Figure 8. Intrinsic dissolution profiles of PZQ-AA (grey triangles), PZQ-2P (orange squares) and 
raw PZQ Form A (blue circles) (mean of triplicated measurements); linear regression trend for each 
profile is represented as dotted lines. 
Finally, the physical stability of the obtained monosolvated forms kept at ambient 
temperature in sealed vials was checked by PXRD. Both PZQ-AA and PZQ-2P exhibited 
a very noticeable physical stability of at least 18 months (as visible from Figure S2 and S3, 
respectively). Additionally, mechanical treatment at 25 Hz for 200 min without interrup-
tions was almost ineffective on both of the two solvates, since the same PXRD patterns 
were collected. Conversely, when PZQ-AA was heated at a constant temperature of 50 °C 
under vacuum over-night, the obtained product, as assessed by means of PXRD, changed 
dramatically and was a mixture of unidentified phases. As for PZQ-2P, the same pattern 
as the fresh sample was obtained, attesting its greater stability, also probably related to 
the higher boiling point of 2-pyrrolidone. 
  




The crystal form screening, conducted by mechanochemistry in the presence of eight 
commonly used solvents, gave crystalline solvates only in the case of acetic acid and 2-
pyrrolidone, even though top solvate-forming solvents (e.g., methanol and acetonitrile) 
[12] were present among the screened additives. 
Since discriminative solvate formation occurs with the solvate selectivity based on 
the solvent’s functionality to provide strong intermolecular interactions, the properties of 
the liquid additives were hence examined to understand the reason of the selective for-
mation of solvates of PZQ. Main physicochemical properties of the solvents, as docu-
mented in literature [39–42,53], are listed in Table 1. 
The failure of solvate outcome is often attributed to the evaporation of the volatile 
liquid during the milling process. However, this was not the case here, due to the very 
short milling time (30 min), the observed milling temperature (about 30 °C, see Section 
2.2) largely inferior to the boiling temperatures of the used solvents. Further, the forming-
solvate acetic acid has a boiling temperature very similar to many other liquid additives 
in the list. Indeed, methanol capability to form solvates by grinding has been previously 
documented despite its volatility [54,55]; however, it is not able to form a solvate with 
praziquantel. This further confirms that the selectivity of solvate formation of praziquan-
tel in presence of acetic acid and 2-pyrrolidone is not due to their boiling point. 
A commonly recognized important parameter for formation of solvates is the solid 
solubility in the solvents. While its importance in solution crystallization is generally rec-
ognized, it is not so in mechanochemical reaction in the presence of liquid additives, about 
which contradictory opinions can be found in the literature [16,56,57]. Indeed, during 
LAG synthesis, high degrees of supersaturation are always present since only small 
amounts of solvent are used, therefore increasing the role of other variables. Additionally, 
in this case, comparing PZQ solubility in different media from literature [53,58,59] with 
our results, and remembering that PZQ is able to yield a hemihydrate in water where is 
sparingly soluble [24], a relationship between solid solubility and solvate formation can-
not be proven. 
In the PZQ molecule, only the oxygen atoms of the amide group can function as hy-
drogen bond acceptors because the free electron pair of the nitrogen atoms are involved 
in π electron delocalization. Additionally, there are three types of C-H acidic hydrogen 
atoms for the generation of attractive secondary C-H···O contacts [6]. Further, PZQ has a 
documented potential to form multicomponent crystals (e.g., cocrystals or hydrates) with 
reagents containing hydrogen bond donors [6,11]. As mentioned in the literature, the 
strength of H-bonding between the solvent and the solute molecules can be evaluated 
through the solvent properties, and the values of α and β, respectively, can be used to 
evaluate the H-bond donation ability and H-bond acceptance ability or electron pair do-
nation ability to form a coordinative bond [40]. As visible from Table 1, the eight studied 
solvents are characterized by variable properties. However, the solvates were only ob-
tained from acetic acid and 2-pyrrolidone. By comparing the parameters of the eight sol-
vents, acetic acid has the highest alpha value, and the lowest cohesive energy density 
(CED). Alpha parameter reflects a good H-bond donor propensity, whereas CED reveals 
the strength of solvent-solvent interactions and hence is involved in the solute-solvent 
interactions. These data can therefore be evoked as the main responsible of the formation 
of the PZQ-AA. As for 2-pyrrolidone, in addition to the H-bond donation to the amide 
group oxygen atom (note that the solvent has intermediate β value in the list), also the 
attractive secondary C-H···O contacts might be involved: this would be in agreement with 
its highest documented β parameter. Further, the very high cohesive energy density value 
of 2-pyrrolidone might not play a role which was conversely suggested previously in ace-
tic acid case. Finally, π parameter, a further classical parameter evoked in solvate for-
mation context [60] describing a combination of polarity and polarizability, did not show 
a correlation with our results. In conclusion, from our survey it can be speculated that 
PZQ solvate formation is not simply dependent on any individual solvent parameter but 
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on the combined impact of solvent hydrogen bond-donor propensities and cohesive en-
ergy density. 
Examining the molecular structure of the newly synthetized PZQ-AA and PZQ-2P, a 
syn conformation of the C=O groups of the piperazinone-cyclohexylcarbonyl segment is 
adopted. Hence, in contrast to known solvated forms (single enantiomers or racemic PZQ 
hemihydrates [6,7,11] providing an anti-conformation of the C=O groups, in the two 
newly synthetized solvates these groups retain the same stereochemistry as the starting 
PZQ Form A. This feature is peculiar and rather counterintuitive, due to the fact that the 
anti-orientation would provide a larger spatial separation of the C=O groups and might 
enable in principle an easier insertion of the complementary hydrogen bond forming func-
tions of solvent molecules. In fact, PZQ has a documented higher propensity to interact 
via hydrogen bonds when in an anti-conformation [6]. This stereochemistry was also the 
most common in the case of PZQ cocrystals with dicarboxylic acids, cited in previous 
structural reports [6]. Noteworthy when grinding process started from PZQ Form B (also 
featuring the anti-conformation), PZQ is switched as well to the anti-antagonism. 
However, considering the syn conformation also in the light of the above-mentioned 
H-bond interactions, it can be hypothesized that this stereochemistry is more favorable 
for the insurgence of secondary attractive H-bonds, in particular in relation to the cyclo-
hexylcarbonyl moiety, where—as a matter of fact—the relatively rigid PZQ molecular 
structure has its limited conformational flexibility. 
Of note is the fact that, contrary to what reported for PZQ hemihydrate [11], the for-
mation of the new solvates depends on the solvent used in the course of grinding rather 
than on the starting solid form of PZQ. In particular, differently from the hemihydrate 
case, is not mandatory to yield the solvates an intermediate amorphous/metastable state, 
but a direct grinding process in the presence of liquid additive is adequate, provided that 
the suitable liquid additive is present. The retention of the original carbonyl stereochem-
istry in both the solvates might be an additional reason. 
Interestingly, this pair of newly discovered solvates belong to the class of isostruc-
tural solvates [12,61–63] since structures belong to the same space group (P-1) and display 
similar unit-cell dimensions (with only small distortions) and conformations, as well as 
isostructural crystal packings. The conformation of the core molecule seems predomi-
nantly responsible for governing the isostructurality. According to this, very similar melt-
ing enthalpies at the DSC and Intrinsic Dissolution Rate values were observed in the two 
solvates, and analogous physical stability was observed. In this latter regard, the results 
are not surprising, since it is known that the liquid insertion in a crystal lattice, even 
though it can sometimes bring some disorder in the structure, can also favor the formation 
of hydrogen bonds and strong interactions that improve the stability of the system, which 
is noticeably remarkable. 
In terms of water solubility and IDR, PZQ-AA and PZQ-2P showed the expected fa-
vorable biopharmaceutical performance, which is superior to that of anhydrous Form A. 
The most usual explanation of such performance is that the negative Gibbs free energy of 
mixing of the organic solvent, released during the dissolution of a solvate, contributes to 
the Gibbs free energy of solution, increasing the thermodynamic driving force for the dis-
solution process [12]. In other words, this is due to the fact that, a non-aqueous solvate 
phase could be considered as being a high-energy form of the solid with respect to disso-
lution in water. As previously said, since the two solvates are nearly isomorphic, it is not 
surprising that the biopharmaceutical performance of the two solvates are very similar. 
5. Conclusions 
The propensity of solvate formation of PZQ was studied by mechanochemical screen-
ing using eight selected solvents. Such screening provided two new solvates, both with 
1:1 host-guest stoichiometry, with acetic acid and 2-pyrrolidone. The crystal structures 
were solved from synchrotron X-ray powder diffraction data: the solvates being isostruc-
tural, unit cell being triclinic. In both structures the acetic acid and 2-pyrrolidone showed 
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a strong interaction with the PZQ molecule via hydrogen bond, providing a physical sta-
bility of at least 18 months. 
Mechanochemical approach has demonstrated also in this case to be a viable process 
for discovering new crystal forms. Although the screening was limited to eight liquids, 
these analyses provided important findings for hypothesizing the possible mechanism of 
interaction between PZQ and the liquid additives, giving reason for the peculiar behavior 
in the presence of acetic acid and 2-pyrrolidone. For the formation of these PZQ solvates, 
differently from previous PZQ hemihydrate, the type of solvent and its capacity of inter-
action with the solid affect the course of the reaction rather than the identity of PZQ crystal 
form used as starting material. 
As PZQ is a drug substance whose absorption is determined by the dissolution rate, 
the demonstration of the existence of solvates, in addition to anhydrous polymorphs and 
hydrates, highlights the need for proper survey of PZQ solid forms landscape and a care-
ful consideration during manufacture and formulation of experimental conditions that 
could be associated with the insurgence of unpredicted drug crystal forms. Further, the 
effect of liquid additives in mechanochemistry requires more systematic work and the 
interplay of various scientific disciplines in order to draw the ultimate picture of solvate 
formation. 
Supplementary Materials: The following are available online at www.mdpi.com/arti-
cle/10.3390/pharmaceutics13101606/s1. Figure S1. PXRD pattern of the solids retrieved after grind-
ing PZQ A and B in presence of different liquid additives and PZQ A as a reference. Figure S2. PZQ-
AA: fresh sample, after 18 months at room temperature *, under vacuum overnight at 50 °C *, 
ground for 200 min at 25 Hz * and PZQ-AA prepared by slurry method. Figure S3. PZQ-2P: fresh 
sample, after 18 months at room temperature*, under vacuum overnight at 50 °C *, ground for 200 
min at 25 Hz * and PZQ-AA prepared by slurry method. Figure S4. Optical microscopy images of 
PZQ-AA and PZQ-2P upon heating (with indication of operating temperature in each image) (Mag-
nification 100×). Figure S5: Crystal packing comparison along axis of (a) PZQ-AA, (b) PZQ-2P and 
(c) PZQ hemihydrate form. Figure S6: FT-IR spectra of PZQ-AA (blue), PZQ-2P (red) and raw PZQ 
Form A (green). Frames highlight diagnostic regions with above-mentioned different colors. Figure 
S7. 13C (100.65 MHz) CPMAS SSNMR spectra of (a) PZQ Form A, (b) PZQ Form B, (c) PZQ-2P, and 
(d) PZQ-AA acquired at 12 kHz. Relevant assignments are reported for the PZQ molecule (b) and 
for the solvent molecules (c,d) resonances. Figure S8. Comparison of experimental and calculated 
13C SSNMR spectra of PZQ-AA (top) and PZQ-2P (bottom). The only significant disagreement is 
found for the COOH signal, at 177.1 and 172.1 ppm in the PZQ-AA calculated and experimental 
spectrum, respectively. The 5 ppm difference may be attributed to the difficulty in modelling the 
electronic environment around an acidic ionizable proton. Figure S9. Quantitative comparison of 
experimental and calculated 13C SSNMR spectra of PZQ-AA (top) and PZQ-2P (bottom). Table S1 
Calculated shift/ppm and calculate shielding/ppm (for atom numbering please refer to Scheme). 
Externally hosted supplementary file S1: Link: http://www.ccdc.cam.ac.uk/structuresDescription 
(Accessed on 27 September 2021): CCDC 2074789 and CCDC 2074793 contain the supplementary 
crystallographic data for Praziquantel acetic acid monosolvate (PZQ-AA) and Praziquantel 2-pyr-
rolidone monosolvate (PZQ-2P). 
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